• Earlier this month, Astera Labs, Inc. reported first-quarter 2026 results showing higher sales and earnings, issued upbeat second-quarter guidance, expanded its Scorpio X-Series and P-Series AI fabric switches, and filed a US$2.05 billion shelf registration linked to an ESOP-related common share offering.
• An interesting angle for investors is how Scorpio’s memory-semantic, software-defined architecture and the COSMOS management stack aim to deepen Astera Labs’ role at the rack-scale layer of AI data centers, potentially increasing its importance in large hyperscaler deployments.
• With Scorpio’s expanded fabric switch family and COSMOS software now in focus, we’ll examine how this news reshapes Astera Labs’ investment narrative.

The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Astera Labs Investment Narrative Recap

To own Astera Labs, you need to believe AI data center spending on open, rack-scale connectivity continues to favor specialist vendors and that Scorpio plus COSMOS can stay technically relevant in a fast-moving interconnect market. The latest Scorpio launches and strong Q1 numbers reinforce the near term catalyst of broader hyperscaler adoption, while the biggest risk remains customer concentration and competing interconnect standards, which this news does not fully resolve.

The new Scorpio X-Series 320-lane smart fabric switch is the most relevant update here, because it directly supports the thesis that Astera can increase its dollar content per AI rack. By targeting the merchant scale-up switch silicon segment projected at US$20,000,000,000 by 2030 and tying it into COSMOS, this launch sits at the center of expectations that Scorpio ramps into large-scale deployments over the next few years.

But while the product momentum is clear, investors should also understand how rising competition in interconnect standards could still affect Astera Labs’ long term pricing power and...

Astera Labs' narrative projects $1.5 billion revenue and $393.5 million earnings by 2028. This requires 34.1% yearly revenue growth and roughly a $293 million earnings increase from $100.2 million today.

Uncover how Astera Labs' forecasts yield a $204.47 fair value, a 12% downside to its current price.

Exploring Other Perspectives

Before this update, the most optimistic analysts were already assuming revenue could reach about US$3.2 billion and earnings about US$921 million by 2029, so if you agree that COSMOS could evolve into a much larger, higher margin software layer than consensus expects, you may see this news very differently from those who focus more on the risks of heavy hyperscaler dependence.

Explore 15 other fair value estimates on Astera Labs - why the stock might be worth as much as 7% more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Astera Labs research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Astera Labs research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Astera Labs' overall financial health at a glance.

Looking For Alternative Opportunities?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Capitalize on the AI infrastructure supercycle with our selection of the 42 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 31 best rare earth metal stocks of the very few that mine this essential strategic resource.
• AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.